Asia Pacific Cancer Vaccines Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Technology, Type, Indication, End User –

05-Dec-2020 Intellasia | BusinessWire | 3:53 AM Print This Post

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Cancer Vaccines Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Technology; Type; Indication; End User, and Country" report has been added to's offering.

Cancer Vaccines Market for Dendritic Cells Cancer Vaccines Segment to Grow at Fastest CAGR during Forecast Period

The market is expected to reach US$3,131.09 million in 2027 from US$861.55 million in 2019; it is estimated to grow at a CAGR of 17.9% from 2020 to 2027.

Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines. The in recombinant cancer vaccines segment held the largest share of the market in 2019. Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.

The Asia Pacific Cancer Vaccines market growth is mainly attributed to factors such as growing prevalence of cancer, and rising government initiatives to prevent it. However, the challenges in cancer vaccines industry like expensive cost restrains the growth of the market.

AstraZeneca, GlaxoSmithKline plc., Aduro Biotech Inc, Pfizer Inc., Sanofi, Bristol-Myers Squibb, Moderna, Inc., OncBioMune Pharmaceuticals Inc., MaxiVAX, Nouscom are among the leading companies operating in the Cancer Vaccines Market.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Research Report Guidance

1.3 Market Segmentation

2. Cancer Vaccines Market - Key Takeaways

3. Research Methodology

4. Cancer Vaccines - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinion

5. Asia Pacific Cancer Vaccines Market - Industry Dynamics

5.1 Key Drivers

5.1.1 Increase in Prevalence of Cancer Worldwide

5.1.2 Initiatives Taken by Global Health Research Organizations and Key Players for Cancer Vaccines

5.2 Key Market Restraints

5.2.1 Less Number of Commercially Available Vaccines for Treatment of Cancer

5.2.2 Higher Cost of Cancer Vaccines

5.3 Key Market Opportunities

5.3.1 Emerging Markets in Developing Countries

5.4 Future Trends

5.4.1 Growing Research and Development Activities

5.5 Impact analysis

6. Cancer Vaccines Market - Regional Analysis

6.1 Asia Pacific Cancer Vaccines Market Revenue Forecast And Analysis

7. Asia Pacific Cancer Vaccines Market Analysis - By Technology

7.1 Overview

7.2 Cancer Vaccines Market Share, by Technology, 2019 and 2027 (%)

7.3 Dendritic Cells Cancer Vaccine

7.4 Recombinant Cancer Vaccines

7.5 Antigen Cancer Vaccines

7.6 Whole Cell Cancer Vaccines

7.7 Viral Vector Cancer Vaccines

8. Cancer Vaccines Market Analysis - By Type

8.1 Overview

8.2 Cancer Vaccines Market Revenue Share, by Type (2019 and 2027)

8.3 Preventive Cancer Vaccines

8.4 Therapeutic Cancer Vaccines

9. Cancer Vaccines Market Analysis - By Indication

9.1 Overview

9.2 Cancer Vaccines Market Revenue Share, by Indication (2019 and 2027)

9.3 Cervical Cancer

9.4 Prostate Cancer

10. Cancer Vaccines Market Analysis - By End Use

10.1 Overview

10.2 Cancer Vaccines Market Revenue Share, by End Use (2019 and 2027)

10.3 Pediatrics

10.4 Adults

11. Cancer Vaccines Market - Geographic Analysis

12. Impact Of COVID-19 Pandemic On Global Cancer Vaccines Market

13. Cancer Vaccines Market - Industry Landscape

13.1 Overview

13.2 Growth Strategies Done by the Companies in the Market, (%)

13.3 Organic Developments

13.3.1 Overview

13.4 Inorganic Developments

13.4.1 Overview

14. Company Profiles

  • AstraZeneca
  • GlaxoSmithKline plc.
  • Aduro Biotech Inc
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Moderna, Inc.
  • OncBioMune Pharmaceuticals Inc.
  • MaxiVAX
  • Nouscom

For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Category: BusinessWire, PRAsia

Print This Post

Comments are closed.